First and only liquid embolic approved for hypervascular tumor embolization

Materializing Solutions

Developing Next generation Resorbable Embolics

Instylla is a privately held company based in Bedford, MA, focused on developing novel resorbable embolic agents to advance interventional radiology, with initial clinical applications in interventional oncology.

"I am excited to have this wonderful new tool in the IR repertoire."

"We are thrilled to be part of such an important milestone in the field of embolization for hypervascular tumors. We look forward to witnessing the many possibilities that the Embrace liquid embolic will bring to the cancer embolization space."

"Embrace is next level! It allows deep hypervascular tumor penetration for total blood flow occlusion. Plus, it resorbs with time so nothing is left behind and no further treatment option is excluded. I love it!"

Solutions & Clinical Results

Embrace™ Hydrogel Embolic System (HES) is the only non-adhesive liquid embolic penetrating to the capillary level for proven targeted hypervascular tumor treatment and favorable target lesion response without recanalization.

The Instylla HES Hypervascular Tumor Study: A prospective, randomized, multicenter, subject and evaluator blinded pivotal trial.

Primary Safety and Effectiveness Endpoints Met on the Instylla HES Hypervascular Tumor study evaluating the Embrace HES against Standard of Care, Transcatheter Arterial Embolization (TAE)/ Transcatheter Arterial Chemoembolization (cTACE) procedures

The Tembo™ Embolic System consists of dry, irregularly shaped, resorbable gelatin particles designed for use in the embolization of hypervascular tumors and occlusion of blood vessels in the peripheral vasculature.

Latest News

Instylla Initiates Commercial Launch with First Use of the Embrace™ Hydrogel Embolic System

Milestone marks the commercial use of the first and only liquid embolic approved for hypervascular tumor embolization supported by a prospective, randomized, controlled clinical trial BEDFORD, Mass., January 28th, 2026 – Instylla, Inc., a privately held company developing novel resorbable

Instylla Gains U.S. FDA Premarket Approval for Embrace™ Hydrogel Embolic System

First and Only Liquid Embolic Approved for Hypervascular Tumor Embolization Supported by a Prospective, Randomized, Controlled, Clinical Trial BEDFORD, Mass., August 7, 2025 – Instylla, Inc., a privately held company developing novel resorbable embolics for peripheral vascular embolization, announced premarket approval

Instylla Appoints MedTech Leader Sean Boyle as Chief Executive Officer

BEDFORD, Mass., Aug 5, 2025 – Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolization, has announced the appointment of Sean Boyle as Chief Executive Officer. A seasoned senior executive with over 15 years of leadership experience